A Deep Dive on the Topgolf Callaway Spinoff – The Special Situations Report Episode #46

Episode Summary

Executive Summary: Episode 46 surveys event-driven developments, led by Abbott’s $23 billion all-cash acquisition of Exact Sciences and Topgolf Callaway’s shift from a planned spin-off to a sale of control to private equity. The hosts also assess potential media and software deals, Zymeworks’ move toward royalties, Biohaven’s clinical and financing setbacks, activist interest in Barrick, and executive departures at IonQ.

Main Topics: Deals in the works and transaction activity: Sinclair disclosed an approximately 8% stake in E.W. Scripps, while regulatory scrutiny clouds Nexstar’s proposed Tegna deal. Paramount Skydance, Comcast, and Netflix reportedly bid for Warner Bros. Discovery, and Thoma Bravo joined interest in Clearwater Analytics. A small bid for biotech Newforia was withdrawn. The hosts also note a pickup in announced deal value. Abbott’s acquisition of Exact Sciences: Abbott agreed to acquire Exact Sciences for $105 per share in cash, a roughly $23 billion transaction. The hosts explain Exact’s cancer-testing business and CancerGuard’s potential, while noting Abbott’s desire to expand diagnostics after COVID-related testing revenue declined and the substantial debt financing likely required. Topgolf Callaway’s change of plan: A planned separation of Topgolf and Callaway was replaced by a deal to sell a 60% stake in Topgolf and Toptracer to Leonard Green & Partners, valuing the business at $1.1 billion. Callaway would focus on golf equipment; the discussion frames the change against Topgolf’s capital needs, slowing venue performance, and the merger’s disappointing economics. Zymeworks pivots toward royalty-based investing: Zymeworks authorized a $125 million buyback despite being a clinical-stage biotech. The hosts connect this to its cash balance, licensed drug candidates and potential milestone payments, and its emerging plan to build a royalty portfolio while continuing some internal research and development. Biohaven’s pipeline setbacks and capital needs: Biohaven’s shares have fallen sharply after drug-development failures, competition, and an FDA rejection of its SCA application. A $200 million secondary offering provides added runway, but the company is cutting R&D spending and concentrating on three programs, with key BHV-7000 trial results expected in late 2025 and the first half of 2026. Activism and leadership changes: Elliott Investment Management reportedly built a large stake in Barrick as the miner refocuses on North American assets after its CEO’s departure. IonQ’s chief revenue officer resigned amid broader executive turnover; the hosts question the company’s commercialization readiness and emphasize the uncertainty and hype in quantum computing.

Key Arguments: A second request from the DOJ can lengthen a merger review and concern arbitrage investors; the hosts also caution that regulatory scrutiny of one broadcaster combination could affect review of other industry deals. Exact Sciences offers Abbott a sizable diagnostics growth opportunity, particularly through early cancer detection, but the all-cash structure is large relative to Abbott’s cash reserves and implies significant borrowing. Topgolf and Callaway had mismatched business economics: venues are capital-intensive and lower-margin, whereas Callaway’s equipment business has different capital needs. Selling control may be more practical than completing the delayed spin-off. Zymeworks’ buyback appears unusual for a clinical-stage biotech, but its cash position and shift toward licensing royalties and capital allocation may help explain the strategy; execution depends on identifying valuable assets. Biohaven faces a serious funding and pipeline challenge: its near-term candidates have faltered, cash burn is high, and its remaining prospects are uncertain or early-stage, making upcoming BHV-7000 readouts important. IonQ’s executive departures and the industry’s limited current commercialization raise questions about how soon independent quantum-computing companies can generate meaningful revenue.

Data Points: Sinclair stake in E.W. Scripps: Approximately 8% - Sinclair built the stake in a smaller broadcaster that owns about 60 local TV stations. Nexstar–Tegna proposed transaction: $6.2 billion; spread a little over 10% - The DOJ issued a second request, which the hosts say may prolong the deal process. October announced M&A activity: 26 deals totaling $112 billion - Compared with about 25 deals worth $58 billion in September. Deals announced in the prior week: $44 billion - The hosts described November as shaping up to be even more active than October. Abbott acquisition of Exact Sciences: $23 billion; $105 per share in cash - Exact Sciences’ stock was reported at $100.90, implying about a 4% spread and nearly 7% annualized if it closed by mid-2026. CancerGuard price and sensitivity: $689 per test; 68% sensitivity across six deadly cancers and 64% overall sensitivity - The test is recommended annually for adults ages 50–84 with no known cancer diagnosis in the prior three years; figures were attributed to the company. Exact Sciences projected revenue: More than $3 billion - Expected for the year; Abbott’s diagnostics sales were expected to exceed $12 billion annually after the deal. Abbott balance sheet: $7.7 billion cash and nearly $13 billion debt - Figures cited for the prior quarter; the hosts note Abbott would likely need substantial additional debt financing. Topgolf transaction: 60% stake sold; $1.1 billion valuation; about $770 million proceeds - Leonard Green & Partners’ deal was expected to close in the first quarter of 2026. Topgolf Callaway business revenue at proposed separation: About $2.5 billion for Callaway and $1.8 billion for Topgolf - Revenue figures cited when the company outlined its planned separation in 2024. Jack Wolfskin sale: $290 million reported sale price versus $476 million purchase price - Callaway bought the German outdoor brand in 2019 and announced its sale to Anta in April. Zymeworks buyback authorization: $125 million, about 7% of market capitalization - The company had nearly $250 million of net cash; its stock was later cited at just over $24. Potential Zymeworks milestones: Up to $440 million for Zihera and $434 million for a prostate-cancer candidate - Milestones depend on regulatory approvals; the latter candidate also carries potential mid-single-digit royalties. Biohaven share performance: Down 80% over the last year; up about 32% post-spin - The hosts contrast this with a prior period when the spun-off company had risen substantially. Biohaven Q3 2025 R&D spending and net loss: About $141 million and $173 million, respectively - The hosts described the cash burn as unsustainable without pipeline or commercial progress. Biohaven secondary offering: About $200 million in gross proceeds - The offering extends the company’s runway following the FDA rejection and pipeline setbacks. Biohaven planned R&D reduction: More than 60% - The company said it would prioritize three programs, including BHV-7000. IonQ share performance: Up 35% in the last year and over 286% since going public - The hosts cautioned that the company’s valuation and prospects reflect substantial hype and that commercialization remains distant.

Pivotal Quotes: "The company will have to raise a large amount of debt to fund this massive deal, considering it's opted not to use its stock for the acquisition and is paying all cash." — Host: Summarizes the financing risk associated with Abbott’s acquisition of Exact Sciences. "The most concerning thing about Biohaven is how quickly the company is burning cash." — Host: Introduces the central financial concern after Biohaven’s clinical setbacks. "If this company turns into another Ligand, the key question would be if they had the right talent to identify and bet on the right candidates." — Host: Frames the execution challenge behind Zymeworks’ potential transition toward royalty investing.

Implications: Investors should distinguish deal spreads from regulatory and financing risk, and assess whether corporate restructurings address underlying economics. For biotech turnarounds, cash runway and credible clinical catalysts are critical; quantum-computing commercialization remains uncertain.